Journal Article

Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease

Sankoh, Serap, Sandborn, William J, Hanauer, Stephen, Fox, Irving, Rutgeerts, Paul, Sands, Bruce E, Colombel, Jean-Frédéric, Lee, Scott, Lukas, Milan, Feagan, Brian G, Xu, Jing, Milch, Catherine, Bressler, Brian, Parikh, Asit, Rosario, Maria, Stephens, Kristin, Fedorak, Richard N

2013

Overview

In this 52-week randomized trial, the α 4 β 7 integrin antibody vedolizumab was effective in treating Crohn's disease. The incidence of serious adverse events was higher with vedolizumab than with placebo. Crohn's disease is a chronic inflammatory bowel disease. 1 Current treatments include glucocorticoids, immunosuppressive agents (i.e., azathioprine, mercaptopurine, or methotrexate), and tumor necrosis factor (TNF) antagonists. 1 – 3 Many patients do not have a response to therapy, 4 and treatments are associated with important toxic effects. 5 , 6 Natalizumab, a monoclonal antibody that modulates gut and brain lymphocyte migration by antagonizing α 4 β 1 and α 4 β 7 integrin–mediated interactions, 7 is efficacious in the treatment of multiple sclerosis 8 , 9 and Crohn's disease. 10 – 12 Its use in patients with Crohn's disease has been limited by the development in some patients of progressive multifocal . . .

• Publisher: Massachusetts Medical Society
• Subject: Adult / Antibodies - blood / Antibodies, Monoclonal, Humanized - adverse effects / Antibodies, Monoclonal, Humanized - immunology / Antibodies, Monoclonal, Humanized - therapeutic use / Antibodies, Monoclonal, Humanized/adverse effects/immunology/therapeutic use / Biological and medical sciences / Clinical trials / Crohn Disease - drug therapy / Crohn's disease / Double-Blind Method / Drug Administration Schedule / Drug Therapy, Combination / Female / Gastroenterology & hepatology / Gastroenterology. Liver. Pancreas. Abdomen / Gastroentérologie & hépatologie / General aspects / Glucocorticoids - therapeutic use / Headache / Human health sciences / Humans / Immunosuppressive Agents - therapeutic use / Induction Chemotherapy / Induction therapy / Inflammatory bowel disease / Infusions, Intravenous - adverse effects / Integrins - antagonists & inhibitors / Integrins - immunology / Integrins/antagonists & inhibitors/immunology / Intravenous administration / Maintenance Chemotherapy / Male / Medical research / Medical sciences / Middle Aged / Monoclonal antibodies / Other diseases. Semiology / Pain / Pharmaceuticals / Remission / Rhinopharyngitis / Sciences de la santé humaine / Stomach. Duodenum. Small intestine. Colon. Rectum. Anus / Ulcers